Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more
Biohit Oyj B (BIOBV) - Total Assets
Latest total assets as of December 2025: €19.80 Million EUR
Based on the latest financial reports, Biohit Oyj B (BIOBV) holds total assets worth €19.80 Million EUR as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biohit Oyj B - Total Assets Trend (2000–2025)
This chart illustrates how Biohit Oyj B’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biohit Oyj B - Asset Composition Analysis
Current Asset Composition (December 2025)
Biohit Oyj B's total assets of €19.80 Million consist of 46.0% current assets and 54.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €3.50 Million | 17.7% |
| Accounts Receivable | €3.60 Million | 18.2% |
| Inventory | €800.00K | 4.0% |
| Property, Plant & Equipment | €1.90 Million | 9.6% |
| Intangible Assets | €700.00K | 3.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Biohit Oyj B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biohit Oyj B's current assets represent 46.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, up from 12.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 38.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 18.2% of total assets.
Biohit Oyj B Competitors by Total Assets
Key competitors of Biohit Oyj B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Biohit Oyj B - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Biohit Oyj B generates 0.79x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Biohit Oyj B generates $ 13.64 in net profit.
Biohit Oyj B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 3.67 | 4.28 |
| Quick Ratio | 2.31 | 3.33 | 3.81 |
| Cash Ratio | 0.97 | 1.25 | 0.00 |
| Working Capital | €5.50 Million | € 8.00 Million | € 6.36 Million |
Biohit Oyj B - Advanced Valuation Insights
This section examines the relationship between Biohit Oyj B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.89 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | 27.7% |
| Total Assets | €19.80 Million |
| Market Capitalization | $19.87 Million USD |
Valuation Analysis
Near Book Valuation: The market values Biohit Oyj B's assets close to their book value ( 1.00x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Biohit Oyj B's assets grew by 27.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biohit Oyj B (2000–2025)
The table below shows the annual total assets of Biohit Oyj B from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €19.80 Million | +27.74% |
| 2024-12-31 | €15.50 Million | +19.97% |
| 2023-12-31 | €12.92 Million | +17.29% |
| 2022-12-31 | €11.02 Million | +14.58% |
| 2021-12-31 | €9.61 Million | -10.80% |
| 2020-12-31 | €10.78 Million | -37.96% |
| 2019-12-31 | €17.37 Million | -2.88% |
| 2018-12-31 | €17.89 Million | -5.33% |
| 2017-12-31 | €18.89 Million | +45.47% |
| 2016-12-31 | €12.99 Million | +10.75% |
| 2015-12-31 | €11.73 Million | -19.16% |
| 2014-12-31 | €14.51 Million | -48.74% |
| 2013-12-31 | €28.30 Million | -29.26% |
| 2012-12-31 | €40.01 Million | -44.02% |
| 2011-12-31 | €71.47 Million | +143.24% |
| 2010-12-31 | €29.38 Million | +7.24% |
| 2009-12-31 | €27.40 Million | +1.08% |
| 2008-12-31 | €27.11 Million | -0.84% |
| 2007-12-31 | €27.34 Million | +0.07% |
| 2006-12-31 | €27.32 Million | -1.91% |
| 2005-12-31 | €27.85 Million | +22.37% |
| 2004-12-31 | €22.76 Million | +4.04% |
| 2003-12-31 | €21.88 Million | -2.40% |
| 2002-12-31 | €22.41 Million | -10.33% |
| 2001-12-31 | €25.00 Million | -82.93% |
| 2000-12-31 | €146.42 Million | -- |